Shared on 01 Nov 25
Fair value Decreased 0.30%Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.
Shared on 18 Oct 25
Fair value Increased 3.70%Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.